- $1.33bn
- $2.34bn
- $1.05bn
- 75
- 83
- 60
- 85
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 489 | 582 | 761 | 904 | 1,052 |
Cost of Revenue | |||||
Gross Profit | 349 | 425 | 556 | 654 | 744 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 396 | 688 | 896 | 1,006 | 998 |
Operating Profit | 93.3 | -106 | -135 | -103 | 53.4 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 92 | -134 | -156 | -111 | 5.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 85.8 | -143 | 282 | -114 | -1.87 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 66.1 | -145 | 310 | -79.7 | -4.21 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 66.1 | -145 | 280 | -79.7 | -4.21 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.604 | -0.732 | 1.64 | 0.284 | 0.337 |
Dividends per Share |